Table 1.
Baseline characteristics and FSS, EDSS, BDI, and FSMC (total, cognition, and motor subscales) outcome for the healthy controls and the two patient groups.
| Control group | No cognitive fatigue | Cognitive fatigue | |
|---|---|---|---|
| Sex (females/males), n (%) | 9/4 (69.2%) | 9/5 (64.3) | 18/10 (64.3) |
| Clinical phenotype n (%) | |||
| Relapsing-remitting | N/A | 12 (85.7) | 18 (64.3) |
| Secondary progressive | 2 (14.3) | 10 (35.7) | |
| No medication/interferons/escalated medications (%)a | 100/0/0 | 15.4/53.8/30.8 | 46.7/40.0/13.3 |
| Age (years) (mean, SD)a | 48.6 (5.0) | 42.8 (12.8) | 50.5 (8.8) |
| Education (years) (median, R)a | 13.0 (5.0) | 12.5 (3) | 10.0 (5.0) |
| FSS (mean, SD)a | 19 (9.87) | 29 (10.25) | 46 (10.64) |
| FSMC cognition (median, R) | 17.0 (26) | 21.0 (14) | 36.5 (21) |
| FSMC motor (mean, SD) | 15.5 (6.5) | 26.21 (6.9) | 38.93 (6.1) |
| Relapses during the evaluation perioda | N/A | 1 out of 14 | 13 out of 28 |
| Relapsing-remitting | N/A | 2 out of 12 | 9 out of 18 |
| Secondary progressive | N/A | 1 out of 2 | 2 out of 10 |
FSS, Fatigue Severity Scale; FSMC, Fatigue Scale for Motor and Cognitive Functions; MS, multiple sclerosis.
aSignificant differences between the MS groups computed as described above.